Cure My Disease

Don't miss your cure!

 Log in / Sign up

Newer sedative faces off against propofol in heart patients

NCT ID NCT07829458

NEW Symptom relief Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers compare two sedatives, remimazolam and propofol, for patients with heart disease who need a transesophageal echocardiogram (TEE), a procedure that uses a tube in the esophagus to take pictures of the heart. Adults scheduled for an elective TEE receive one of the two drugs by IV, with doses adjusted to keep them comfortable. The study tracks how often blood pressure drops during the procedure, whether the TEE is completed successfully, how long recovery takes, and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remimazolam, a sedative drug, compared with propofol
What this could lead to
If remimazolam works as well as propofol with fewer blood pressure drops, it could become a preferred sedative for heart patients during TEE procedures.
What could go wrong
This is a single-center study of 210 patients, so results may not apply to all hospitals or patient groups. Remimazolam can still cause low blood pressure or other side effects, and it may not prove better than propofol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age and older * all cardiac patients undergoing elective TEE examination Exclusion Criteria: * Patients with hypersensitivity to dextrans * Emergent procedures * Patient with allergy to any of the anesthetic agents * Patient refusal

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anesthesia Cardiac disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mount Sinai Morningside

    New York, New York, 10025, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.